結(jié)直腸癌（colorectal cancer，CRC）的全球患病率日益增加，盡管相關(guān)治療研究取得了一定進(jìn)展，但由于存在耐藥、有效率低等問題，結(jié)直腸癌的死亡率仍位居前3。越來越多的證據(jù)表明，黃芩的提取物黃芩苷及黃芩素作為新型小分子抑制劑，不僅具有良好的抗CRC作用，且不易誘導(dǎo)癌細(xì)胞產(chǎn)生耐藥性。對黃芩苷及黃芩素這2種黃酮類化合物在CRC治療中的研究現(xiàn)狀進(jìn)行系統(tǒng)綜述，回顧和討論了其在抑制癌細(xì)胞增殖及侵襲轉(zhuǎn)移、誘導(dǎo)癌細(xì)胞死亡、調(diào)節(jié)腫瘤微環(huán)境（tumor microenvironment，TME）等方面的潛在作用及相關(guān)機(jī)制，以期為CRC的治療方案提供新思路。

The prevalence of colorectal cancer (CRC) is increasing globally, and despite some advances were got in related treatments, CRC still ranks among the top three in terms of mortality rate due to the problems of drug resistance and low efficiency. There is increasing evidence that baicalin and baicalein, extracts of the traditional Chinese medicine Scutellaria baicalensis, as novel small-molecule inhibitors, not only have good anticolorectal cancer effects, but also are not easy to induce drug resistance in cancer cells. In this paper, a systematic review of the current research status of baicalin and baicalein, two flavonoids, in the treatment of colorectal cancer was presented, reviewing and discussing their potential roles and related mechanisms in inhibiting the proliferation and invasion and metastasis of cancer cells, inducing the death of cancer cells, and regulating the tumour microenvironment (TME), with the aim of providing new ideas for the therapeutic protocols of CRC.

R286.2

四川省科技廳自然科學(xué)基金青年項目（2023NSFSC1830）